Inventor · disambiguated record
Amit Nathwani
Also filed as: NATHWANI AMIT
27 granted patents·11 pending applications·133 citations·filing 2010–2025
95Inventor score
Files withUCL BUSINESS LTD20UCL BUSINESS PLC10BIOMARIN PHARM INC5FREELINE THERAPEUTICS LTD1NATHWANI AMIT1
Top patents by PatentIndex Score
38 records- 0196US9504762B2Adeno-associated virus factor VIII vectorsBIOMARIN PHARM INC·Filed 2014·Granted Nov 29, 2016·28 cites·9 claims
- 0296US9447168B2Nucleic acid molecules encoding modified factor VIII proteinsUCL BUSINESS PLC·Filed 2013·Granted Sep 20, 2016·18 cites·8 claims
- 0393US10414803B2CapsidUCL BUSINESS PLC·Filed 2016·Granted Sep 17, 2019·14 cites·6 claims
- 0491US9764045B2Optimised coding sequence and promoterUCL BUSINESS PLC·Filed 2015·Granted Sep 19, 2017·14 cites·3 claims
- 0590US10124041B2Methods of delivering factor VIII encoding nucleic acid sequencesUCL BUSINESS PLC·Filed 2016·Granted Nov 13, 2018·4 cites·8 claims
- 0688US11723925B2ROR1 CAR T-cellsUCL BUSINESS LTD·Filed 2018·Granted Aug 15, 2023·6 cites·16 claims
- 0788US10709796B2Optimised coding sequence and promoterUCL BUSINESS PLC·Filed 2017·Granted Jul 14, 2020·4 cites·6 claims
- 0888US9393323B2Optimised coding sequence and promoterNATHWANI AMIT·Filed 2010·Granted Jul 19, 2016·22 cites·8 claims
- 0988US2025108093A1Factor VIII SequencesUCL BUSINESS LTD·Filed 2024·Application pending·0 cites
- 1087US11517631B2Factor IX encoding nucleotidesUCL BUSINESS LTD·Filed 2019·Granted Dec 6, 2022·2 cites·14 claims
- 1187US11306142B2Bispecific antibodies to ROR1 and CD3UCL BUSINESS LTD·Filed 2018·Granted Apr 19, 2022·5 cites·16 claims
- 1287US10792336B2Method of treating hemophilia AUCL BUSINESS PLC·Filed 2018·Granted Oct 6, 2020·2 cites·12 claims
- 1386US11466083B2ROR1 antibodiesUCL BUSINESS LTD·Filed 2018·Granted Oct 11, 2022·4 cites·19 claims
- 1485US10463718B2Adeno-associated virus factor VIII vectorsBIOMARIN PHARM INC·Filed 2016·Granted Nov 5, 2019·3 cites·10 claims
- 1585US10413598B2Factor IX gene therapyUCL BUSINESS PLC·Filed 2015·Granted Sep 17, 2019·3 cites·20 claims
- 1683US12239692B2Adeno-associated virus factor VIII vectorsBIOMARIN PHARM INC·Filed 2022·Granted Mar 4, 2025·0 cites·5 claims
- 1780US2023241180A1Factor VIII SequencesUCL BUSINESS LTD·Filed 2022·Application pending·0 cites
- 1879US10842885B2Factor IX encoding nucleotidesUCL BUSINESS LTD·Filed 2018·Granted Nov 24, 2020·2 cites·24 claims
- 1979US2025127922A1CapsidUCL BUSINESS PLC·Filed 2024·Application pending·0 cites
- 2078US2025066472A1Ror1 antibodiesUCL BUSINESS LTD·Filed 2024·Application pending·0 cites
- 2176US11406690B2Adeno-associated virus factor VIII vectorsBIOMARIN PHARM INC·Filed 2019·Granted Aug 9, 2022·0 cites·5 claims
- 2276US2025332224A1Adeno-Associated Virus Factor VIII VectorsBIOMARIN PHARM INC·Filed 2025·Application pending·0 cites
- 2374US11419920B2Factor VIII sequencesUCL BUSINESS LTD·Filed 2020·Granted Aug 23, 2022·0 cites·9 claims
- 2474US10426845B2Diabetes gene therapyUCL BUSINESS PLC·Filed 2016·Granted Oct 1, 2019·2 cites·16 claims
- 2571US12257319B2Optimised coding sequence and promoterUCL BUSINESS LTD·Filed 2020·Granted Mar 25, 2025·0 cites·20 claims
- 2670US2023220073A1Ror1 antibodiesUCL BUSINESS LTD·Filed 2022·Application pending·0 cites
- 2769US2022331409A1Factor ix gene therapyUCL BUSINESS LTD·Filed 2022·Application pending·0 cites
- 2868US11344608B2Factor IX gene therapyUCL BUSINESS LTD·Filed 2019·Granted May 31, 2022·0 cites·14 claims
- 2967US12370268B2Fabry disease gene therapyUCL BUSINESS LTD·Filed 2021·Granted Jul 29, 2025·0 cites·15 claims
- 3067US12138318B2CapsidUCL BUSINESS LTD·Filed 2019·Granted Nov 12, 2024·0 cites·15 claims
- 3166US12209262B2Factor IX encoding nucleotidesUCL BUSINESS LTD·Filed 2019·Granted Jan 28, 2025·0 cites·20 claims
- 3263US2022204621A1Bispecific antibodies to ror1 and cd3UCL BUSINESS LTD·Filed 2022·Application pending·0 cites
- 3362US2018161403A1Adeno-associated virus factor viii vectorsUCL BUSINESS PLC·Filed 2017·Application pending·0 cites
- 3455US11103596B2Fabry disease gene therapyUCL BUSINESS LTD·Filed 2016·Granted Aug 31, 2021·0 cites·18 claims
- 3550US11077208B2Wilson's disease gene therapyUCL BUSINESS LTD·Filed 2016·Granted Aug 3, 2021·0 cites·10 claims
- 3650US2024261433A1PolypeptideFREELINE THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 3748US12331331B2PolynucleotidesSPUR THERAPEUTICS LTD·Filed 2020·Granted Jun 17, 2025·0 cites·7 claims
- 3847US2021395714A1Modified factor ix polypeptidesUCL BUSINESS LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Amit Nathwani files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →